KRAS and colorectal cancer: We found that scale expression of RGD-p21Ras-scFv have anti-tumor activity in vitro, since many drugs were developed with good in vitro effects but poor in vivo effects and poor safety [37], we selected the KRAS wild-type colorectal cancer cell line HT29 and the KRASG12V mutant colorectal cancer cell line SW480 with good in vitro effects to establish a nude mouse xenograft tumor model and treated with RGD-p21Ras-scFv administration.